Eastern Virginia Medical School
evms.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
56
Active
6
Phase 3
5
Total enrollment
6,473
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Use of insulin glargine once daily | — | — | — | — | — | 1 | |
| Use of insulin glargine twice daily | — | — | — | — | — | 1 | |
| Oxytocin plus Foley Catheter | — | — | — | — | — | 1 | |
| Oxytocin | — | — | — | — | — | 1 | |
| 5% Dextrose | — | — | — | — | — | 1 | |
| Lactate Ringer | — | — | — | — | — | 1 | |
| THC-free CBD Oil | — | — | — | — | — | 1 |
Next readouts
- 2024-03
- 2026-03
- 2026-07-30
- 2027-12-01
Top conditions
- Adherence, Medication3
- Sleep Apnea, Obstructive3
- Pregestational Diabetes2
- Safety Issues2
- Electronic Cigarette Use1
- Hospital Acquired Infection1
- Fibroid Uterus1
- Abnormal Uterine Bleeding1
Frequently asked questions about Eastern Virginia Medical School
- How many clinical trials does Eastern Virginia Medical School have on ClinicalTrials.gov?
- Eastern Virginia Medical School is listed as the lead sponsor on 56 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Eastern Virginia Medical School's trials are in Phase 3?
- 5 of Eastern Virginia Medical School's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does Eastern Virginia Medical School focus on?
- Eastern Virginia Medical School's most-studied conditions on ClinicalTrials.gov are Adherence, Medication, Sleep Apnea, Obstructive, Pregestational Diabetes, Safety Issues, Electronic Cigarette Use.
- When are Eastern Virginia Medical School's next clinical trial readouts?
- Eastern Virginia Medical School has 4 upcoming primary-completion readouts tracked here; the soonest is “Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease”, expected around 2024-03.